Advertisement

Tumor Biology

, Volume 37, Issue 12, pp 15743–15751 | Cite as

TRPV6 is a prognostic marker in early-stage cervical squamous cell carcinoma

  • Fei Sun
  • Lu Xiao
  • Xin-Xing Jang
  • Ying Xiong
  • Qi Li
  • Xiao-jing Yue
  • Yun-Jian Wei
  • Yan-Xing Wei
  • Yan-Lin Ma
  • Yan-Hong Yu
Original Article
  • 240 Downloads

Abstract

Transient receptor potential vanilloid 6 (TRPV6) has been shown to promote caner proliferation in several solid tumors, leading to unfavorable clinical outcomes. Our study aimed to elucidate the clinical significance of TRPV6 in patients with early-stage cervical squamous cell carcinoma (CSCC). The mRNA expression of TRPV6 was measured in 12 paired early-stage CSCC specimens and six cervical carcinoma cell lines using quantitative real-time PCR (qRT-PCR). Western blotting and immunohistochemistry (IHC) were employed to examine the protein expression level of TRPV6 in four paired specimens, 175 paraffin-embedded early-stage CSCC specimens, and 50 normal cervical tissues (NCTs), respectively. Statistical analyses were performed to evaluate the clinical significance of TRPV6 expression. The expressions of TRPV6 mRNA and protein were both significantly downregulated in early-stage CSCC tissues and cervical cancer cell lines. IHC analyses revealed that TRPV6 was downregulated in 136 (77.7 %) of 175 early-stage CSCC specimens. Moreover, TRPV6 expression in early-stage CSCC was significantly correlated with the tumor stage (P < 0.001), tumor growth type (P < 0.001), tumor size (P = 0.008), and differentiation grade (P = 0.003). The early-stage CSCC patients with a low TRPV6 expression level had a short progress-free survival (PFS) and overall survival (OS) duration. Univariate and multivariate analyses identified TRPV6 as an independent prognostic factor for early-stage CSCC patients’ survival. We demonstrated that TRPV6 was downregulated in CSCC, which was correlated with unfavorable survival outcomes of early-stage CSCC patients. TRPV6 may be used as a novel prognostic marker for early-stage CSCC.

Keywords

TRPV6 Early-stage squamous cell cervical carcinoma Prognosis Biomarker 

Notes

Acknowledgments

This work was supported by grant from the State Key Development Programs of China (2012CB966502 to Y.Y. and Y.M.), grant from the International Science & Technology Cooperation Program of China (2014DFA30180 to Y.M.), grants from the National Natural Science Foundation of China (81471464 to Y.Y.; 81260032, 81060016, and 31140021 to Y.M.; 81060175 and 81460034 to Q.L.), grants from the Key International Cooperation Program of Science and Technology Department of Hainan Province (GJXM201106 to Y.M.), and grant from the key program of Hainan Province (ZDZX2013003 to Y.M.).

Compliance with ethical standards

Conflicts of interest

None.

References

  1. 1.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.CrossRefPubMedGoogle Scholar
  2. 2.
    Kodama J, Seki N, Masahiro S, Kusumoto T, Nakamura K, Hongo A, Hiramatsu Y. Prognostic factors in stage IB-IIB cervical adenocarcinoma patients treated with radical hysterectomy and pelvic lymphadenectomy. J Surg Oncol. 2010;101:413–7.PubMedGoogle Scholar
  3. 3.
    Sedlis A, Bundy BN, Rotman MZ, Lentz SS, Muderspach LI, Zaino RJ. A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: a gynecologic oncology group study. Gynecol Oncol. 1999;73:177–83.CrossRefPubMedGoogle Scholar
  4. 4.
    Curtin JP, Hoskins WJ, Venkatraman ES, Almadrones L, Podratz KC, Long H, Teneriello M, Averette HA, Sevin BU. Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol. 1996;61:3–10.CrossRefPubMedGoogle Scholar
  5. 5.
    Thigpen T, Shingleton H, Homesley H, Lagasse L, Blessing J. Cis-Platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the gynecologic oncology group. Cancer. 1981;48:899–903.CrossRefPubMedGoogle Scholar
  6. 6.
    Clapham DE, Runnels LW, Strubing C. The TRP ion channel family. Nat Rev Neurosci. 2001;2:387–96.CrossRefPubMedGoogle Scholar
  7. 7.
    Hoenderop JG, Voets T, Hoefs S, Weidema F, Prenen J, Nilius B, Bindels RJ. Homo- and heterotetrameric architecture of the epithelial Ca2+ channels TRPV5 and TRPV6. EMBO J. 2003;22:776–85.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Peng JB, Chen XZ, Berger UV, Vassilev PM, Tsukaguchi H, Brown EM, Hediger MA. Molecular cloning and characterization of a channel-like transporter mediating intestinal calcium absorption. J Biol Chem. 1999;274:22739–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Bolanz KA, Hediger MA, Landowski CP. The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther. 2008;7:271–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Lehen’Kyi V, Flourakis M, Skryma R, Prevarskaya N. TRPV6 channel controls prostate cancer cell proliferation via Ca2+/NFAT-dependent pathways. Oncogene. 2007;26:7380–5.CrossRefPubMedGoogle Scholar
  11. 11.
    Zhang S, Xie X, Wen J, Luo K, Liu Q, Yang H, Hu Y, Fu J. TRPV6 plays a new role in predicting survival of patients with esophageal squamous cell carcinoma. Diagn Pathol. 2016;11.Google Scholar
  12. 12.
    Chow J, Norng M, Zhang J, Chai J. TRPV6 mediates capsaicin-induced apoptosis in gastric cancer cells—mechanisms behind a possible new “hot” cancer treatment. Biochim et Biophys Acta (BBA) - Mol Cell Res. 2007;1773:565–76.CrossRefGoogle Scholar
  13. 13.
    Fixemer T, Wissenbach U, Flockerzi V, Bonkhoff H. Expression of the Ca2+-selective cation channel TRPV6 in human prostate cancer: a novel prognostic marker for tumor progression. Oncogene. 2003;22:7858–61.CrossRefPubMedGoogle Scholar
  14. 14.
    Peleg S, Sellin JH, Wang Y, Freeman MR, Umar S. Suppression of aberrant transient receptor potential cation channel, subfamily V, member 6 expression in hyperproliferative colonic crypts by dietary calcium. Am J Physiol Gastrointest Liver Physiol. 2010;299:G593–601.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bartik L, Whitfield GK, Kaczmarska M, Lowmiller CL, Moffet EW, Furmick JK, Hernandez Z, Haussler CA, Haussler MR, Jurutka PW. Curcumin: a novel nutritionally derived ligand of the vitamin D receptor with implications for colon cancer chemoprevention. J Nutr Biochem. 2010;21:1153–61.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Peng JB, Chen XZ, Berger UV, Weremowicz S, Morton CC, Vassilev PM. Human calcium transport protein CaT1. Biochem Biophys Res Commun. 2000;278:326–32.CrossRefPubMedGoogle Scholar
  17. 17.
    Hoenderop JG, Vennekens R, Müller D, Prenen J, Droogmans G, Bindels RJ, Nilius B. Function and expression of the epithelial Ca2+ channel family: comparison of mammalian ECaC1 and 2. J Physiol. 2001;537:747–61.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Fei Sun
    • 1
  • Lu Xiao
    • 1
  • Xin-Xing Jang
    • 2
  • Ying Xiong
    • 3
  • Qi Li
    • 2
  • Xiao-jing Yue
    • 1
  • Yun-Jian Wei
    • 2
  • Yan-Xing Wei
    • 1
  • Yan-Lin Ma
    • 1
    • 2
  • Yan-Hong Yu
    • 1
  1. 1.Department of Obstetrics and Gynecology, Nanfang HospitalSouthern Medical UniversityGuangdongChina
  2. 2.Hainan Provincial Key Laboratory for Human Reproductive Medicine and Genetic Research, Affiliated Hospital of Hainan Medical UniversityHainan Medical UniversityHaikouChina
  3. 3.Department of Gynecologic OncologySun Yat-sen University Cancer CenterGuangzhouChina

Personalised recommendations